BOSTON, Mass. and SAN DIEGO, Calif. – March 19, 2024 – Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science…
BOSTON, Mass. and SAN DIEGO, Calif. – February 28, 2024 – Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the…
BOSTON, Mass. and SAN DIEGO, Calif. – January 16, 2024 – Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the…
BOSTON, Mass. and SAN DIEGO, Calif. – January 3, 2024 – Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the…
BOSTON and SAN DIEGO – October 30, 2023 – Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated…
BOSTON and SAN DIEGO – September 7, 2023 – Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of…
Funding to support ongoing clinical programs in seizure and psychiatric disorders and precision neuromedicine discovery platform Raymond Kelleher, M.D., Ph.D.,…
Board to be co-chaired by two Nobel laureates Members include world-renowned experts in ion channel signaling, seizure disorders and the…
Series A financing led by Third Rock Ventures with participation from ARCH Venture Partners and Johnson & Johnson Innovation-JJDC, Inc….
